FIB-4 False Negatives in MASLD: Clinical Phenotypes and an Augmented Triage Model
Date:
Oral presentation FP5-2 (Abstract No. 10340), Saturday 19 September 2026. Recipient of the APASL STC 2026 Kumamoto International Travel Award.
The talk shows that the guideline-recommended FIB-4 index misses significant (F2+) liver fibrosis in 16.6% of MASLD patients it classifies as low risk. The miss rate rises to 37.7% at BMI ≥ 40 kg/m² and is 2.5-fold higher in diabetes. The talk then introduces FIB-4 Plus, which adds BMI, waist circumference and the Hepatic Steatosis Index (AUROC 0.837 vs. 0.749 for the NAFLD Fibrosis Score; DeLong p = 0.019).
Presenting FP5-2 in Free Papers 5-1: MASLD/ALD 1, APASL STC 2026 Kumamoto, 19 September 2026.
Receiving the APASL STC 2026 Kumamoto International Travel Award (far left).